DNA methylation associates with survival in non-metastatic clear cell renal cell carcinoma
Open Access
- 14 January 2019
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 19 (1) , 65
Abstract
Clear cell renal cell carcinoma (ccRCC) is the most common subtype among renal cancer and is associated with poor prognosis if metastasized. Up to one third of patients with local disease at diagnosis will develop metastasis after nephrectomy, and there is a need for new molecular markers to identify patients with high risk of tumor progression. In the present study, we performed genome-wide promoter DNA methylation analysis at diagnosis to identify DNA methylation profiles associated with risk for progress. Diagnostic tissue samples from 115 ccRCC patients were analysed by Illumina HumanMethylation450K arrays and methylation status of 155,931 promoter associated CpGs were related to genetic aberrations, gene expression and clinicopathological parameters. The ccRCC samples separated into two clusters (cluster A/B) based on genome-wide promoter methylation status. The samples in these clusters differed in tumor diameter (p < 0.001), TNM stage (p < 0.001), morphological grade (p < 0.001), and patients outcome (5 year cancer specific survival (pCSS5yr) p < 0.001 and cumulative incidence of progress (pCIP5yr) p < 0.001. An integrated genomic and epigenomic analysis in the ccRCCs, revealed significant correlations between the total number of genetic aberrations and total number of hypermethylated CpGs (R = 0.435, p < 0.001), and predicted mitotic age (R = 0.407, p < 0.001). We identified a promoter methylation classifier (PMC) panel consisting of 172 differently methylated CpGs accompanying progress of disease. Classifying non-metastatic patients using the PMC panel showed that PMC high tumors had a worse prognosis compared with the PMC low tumors (pCIP5yr 38% vs. 8%, p = 0.001), which was confirmed in non-metastatic ccRCCs in the publically available TCGA-KIRC dataset (pCIP5yr 39% vs. 16%, p < 0.001). DNA methylation analysis at diagnosis in ccRCC has the potential to improve outcome-prediction in non-metastatic patients at diagnosis.Keywords
Funding Information
- Medicinska fakulteten, Umeå Universitet
- Lion's Cancer Research Foundation, Umeå (LPK)
- Kempestiftelserna (nr)
- Cancerfonden
- Västerbotten Läns Landsting (nr)
- Uppsala-Umeå Comprehensive Cancer Consortium (nr)
This publication has 56 references indexed in Scilit:
- Genome-wide signatures of differential DNA methylation in pediatric acute lymphoblastic leukemiaGenome Biology, 2013
- A beta-mixture quantile normalization method for correcting probe design bias in Illumina Infinium 450 k DNA methylation dataBioinformatics, 2012
- High-expression of ZBP-89 correlates with distal metastasis and poor prognosis of patients in clear cell renal cell carcinomaBiochemical and Biophysical Research Communications, 2012
- Genomic copy number alterations in clear cell renal carcinoma: associations with case characteristics and mechanisms of VHL gene inactivationOncogenesis, 2012
- Single-CpG-resolution methylome analysis identifies clinicopathologically aggressive CpG island methylator phenotype clear cell renal cell carcinomasCarcinogenesis, 2012
- Epigenetics of renal cell carcinoma: the path towards new diagnostics and therapeuticsGenome Medicine, 2010
- Genome‐wide profiling of chromosomal alterations in renal cell carcinoma using high‐density single nucleotide polymorphism arraysInternational Journal of Cancer, 2009
- Telomere Length in Peripheral Blood Predicts Survival in Clear Cell Renal Cell CarcinomaCancer Research, 2009
- Genetic Clustering of Clear Cell Renal Cell Carcinoma Based on Array-Comparative Genomic Hybridization: Its Association with DNA Methylation Alteration and Patient OutcomeClinical Cancer Research, 2008
- The TNM system: Our language for cancer careJournal of Surgical Oncology, 2002